New combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2: Food as Medicine Research from City Of Hope
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/0 Comments/in Observational, Post-hoc, Retrospective studies/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/0 Comments/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/1 Comment/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/0 Comments/in Artificial Intelligence/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025
- Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors August 29, 2025